Liquidia's 2025 EPS misses analyst expectations

Overview

• Biopharmaceutical firm's YUTREPIA sales led to second consecutive profitable qtr

• Company ended 2025 with $190.7 mln cash, up $33.2 mln from Q3

• EPS for 2025 missed analyst expectations

Outlook

• Liquidia plans to deepen prescriber adoption and grow its sales force in 2026

• Company aims to expand YUTREPIA's clinical evidence through multiple new studies

• Liquidia to advance L606 into pivotal trials, funded from operations

Result Drivers

• YUTREPIA SALES - Strong sales of YUTREPIA contributed to second consecutive profitable quarter

• PATIENT ADOPTION - Over 2,900 patients treated with YUTREPIA since launch, indicating strong market adoption

• CASH POSITION - Ended 2025 with $190.7 mln in cash, an increase of $33.2 mln from Q3, reflecting financial strength

Company press release: ID:nGNX5Dc07y

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Liquidia Corp is $49.00, about 42.5% above its March 4 closing price of $34.38

• The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 19 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.